Published by Josh White on 25th June 2024
(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.
URL: http://www.digitallook.com/dl/news/story/34384424/...